Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2020-06-24 Regulatory Filings
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma announces first patient dosed in Phase 2 trial with long-acting GLP-1/glucagon dual agonist in obesity/diabetes
Regulatory Filings Classification · 95% confidence The document is a press release from Zealand Pharma announcing the dosing of the first patient in a Phase 2 clinical trial. It details the nature of the trial, the financial milestone payment associated with the event, and provides contact information for investor relations. While it mentions an attachment, the document itself is a standard corporate announcement regarding operational/clinical progress, which falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement that does not fit into more specific categories like M&A, Earnings, or Dividends.
2020-06-24 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a press release titled "Zealand Pharma announces first patient dosed in Phase 2 trial..." It details a clinical trial milestone, a payment received, and provides background on the drug candidate and the company. This format—a news announcement regarding a specific corporate or operational event (clinical trial progress, milestone payment)—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management discussion (MDA), and it announces key operational news that often accompanies earnings periods or serves as a material update, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the nature of announcing a clinical milestone and associated payment, which is material non-public information, it functions as a regulatory disclosure. However, since it is a specific announcement of operational progress rather than a standardized financial report or a generic filing, and it is not a proxy statement (DEF 14A) or a dividend notice (DIV), the most appropriate general category for material, non-standardized announcements is often RNS, unless it is clearly an earnings highlight (ER). Since it is a specific, time-sensitive operational update, and not a summary of quarterly results, RNS is a strong candidate. If we consider the context of financial reporting, announcements of material events like this are often released alongside or in lieu of a formal ER. Given the options, and that it is a direct announcement of a material event (dosing patient, triggering payment), it is a regulatory announcement. It is not a proxy (DEF 14A), not a dividend (DIV), not a management discussion (MDA), and not a full report (10-K/IR). It is a specific corporate update, which often falls under RNS or ER. Since it is not explicitly summarizing quarterly financials, RNS (Regulatory Filings/General Announcement) is the safest classification for a material press release that doesn't fit other specific categories.
2020-06-24 English
Zealand Pharma major shareholder announcement: Sunstone Life Science Ventures
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding a change in shareholding status (Sunstone Life Science Ventures falling below the 5% threshold). This falls directly under the definition of a Major Shareholding Notification, which is used to report when a shareholder crosses specific ownership thresholds.
2020-06-23 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 99% confidence The document is titled 'Zealand Pharma major shareholder announcement' and explicitly states it is announcing the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act regarding changes in shareholding percentages by a major shareholder (Sunstone Life Science Ventures). This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds.
2020-06-23 English
Zealand Pharma completes registration of capital increase
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding the completion and registration of a capital increase (issuance of new shares). It details the number of new shares issued, the impact on total share capital, and the registration with the Danish Business Authority. This falls under the category of share issuance and capital changes.
2020-06-22 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 98% confidence The document is a company announcement titled "Zealand Pharma completes registration of capital increase." It explicitly details the registration of a capital increase involving 2,684,461 new ordinary shares following a directed issue and private placement. This action directly relates to changes in the company's capital structure and fundraising activities. Based on the definitions, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a general regulatory filing (RNS) because it fits a specific category, nor is it an announcement of a report (RPA).
2020-06-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.